Feature | September 13, 2013| Patrick Antoun, M.D., and Jeffrey A. Breall, M.D., Ph.D.

Justifying the Use of Vascular Closure Devices

Some centers use closure devices to speed ambulation, cut nursing time

Vascular closure devices (VCD) were first introduced in the early 1990s with a goal to achieve quick hemostasis, thus reducing patients’ stay in the hospital (shorter time to ambulation) as well as faster turnover times for cardiac catheterization laboratories. 

All closure devices have a known cost, as well as a finite failure and complication rate. Perhaps this is why VCDs still face resistance in many institutions. Although percutaneous coronary intervention (PCI) using coronary stents is now standard of care, many new devices and/or treatment of bifurcation lesions require larger sheath and guidecatheter sizes. It thus seems intuitive to move away from bulky uncomfortable sand bags and long hours of bed rest when trying to achieve post-procedural hemostasis. However, VCDs are still not widely used and this is driven, in part, by the lack of reimbursement of such devices to this date. The Centers for Medicare and Medicaid Services (CMS), for example, does not reimburse for any of these items specifically, and the commercial indemnity carriers are mixed, but tend to follow the CMS practice.

Types of Devices and Usage

VCDs exist in a variety of models. These include plug, patch, suture and staple models. Many companies have improved on their basic designs in an effort to decrease complication rates while keeping these devices fast and easy to deploy. Several studies followed by meta-analyses were published to date demonstrating non-inferiority to manual compression in terms of their complication rates and patient comfort. 

However, what VCDs offer that manual compression does not, is essentially better cath lab efficiency — probably faster patient ambulation times and subsequent discharge. In fact, these devices have proven to be very convenient following PCI where the patient can be discharged the same day, even if their procedures were performed late on their appointment day. Although the latter observation was never backed by a solid randomized control trial, it is our personal approach to discharge all uncomplicated elective PCIs on the same day. Some authors suggested a cost benefit with the routine use of VCDs with PCI. However, VCDs may make less sense, in an era of increasing radial access use. Certainly the VCD may be replaced by a radial wristband compression device, but a simple gauze and tape may accomplish the same thing at a lower cost during radial interventions. What about routine diagnostic angiography? There is no definite answer. With the use of smaller catheters during routine diagnostic studies, there really is no need for the use of VCDs. Hemostasis is usually quickly achieved with minimal patient discomfort, even with same day discharge. 

Anticoagulation and Operator Skill

Increasing use of bivalirudin in many labs with less intense anticoagulation during PCI has accomplished two things — less access site bleeding and the appearance of more effective VCDs. How much VCD efficacy over the past 10 years is a result of VCD advances versus changes in anticoagulation strategy is only speculative.

Operator skill also plays a large role with these devices. Most manufacturers (as well as the FDA) require that the first handful of cases be proctored by a sales representative or clinical specialist. Vendors often blame adverse outcomes on inexperienced operators rather than the device itself. Certainly there is no device that is “fool-proof” (although device reps may try to make you believe otherwise). Some require several steps in a specific sequence to use the device properly. Our experience would suggest the more frequently a device is used, the greater its success rate.

Appropriate Use 

VCDs can be very useful when used appropriately in select patients. There are no guidelines to date that dictate their optimal use. Well-designed randomized trials are perhaps needed to answer once and for all the concerns raised by published meta-analyses thus far (although this is unlikely to occur). This could be followed by developing appropriate use criteria for VCDs that would in turn facilitate renegotiation of their reimbursement. As in many other interventional cardiology arenas, the landscape, technologies and practice patterns are rapidly changing, making hard and fast recommendations somewhat difficult.   

Comparison Chart

This article served as an introduction to 3 comparison charts covering hemostasis management devices. Links to the charts for "Hemostasis Management Compression Devices," "Hemostasis Management Hemostatic Pads," and "Vascular Closure Devices" can be found by clicking on the "comparison charts" tab at the top of the page.  Participants on the charts include:

  • Abbott Vascular — www.abbottvascular.com

AccessClosure Inc. — www.accessclosure.com

Advanced Vascular Dynamics — www.compressar.com

Arstasis — www.arstasis.com

Biolife LLC — www.statseal.com

Maquet — ca.maquet.com

Marine Polymer Technologies — www.syvek.com

St. Jude Medical — www.sjm.com

Terumo Medical — www.terumois.com

TZ Medical Inc. — www.tzmedical.com

Vascular Solutions — www.vasc.com

Z-Medica LLC — www.z-medica.com

Scranton Gillette Communications obtained the model specifications
from the manufacturers.

 

 

Related Content

LimFlow System, critical limb ischemia, CLI, CE Mark
News | Stents Peripheral| December 08, 2016
LimFlow SA announced in November that it received the CE Mark for its fully percutaneous LimFlow System designed for...
Sponsored Content | Videos | Angiography| December 07, 2016
Shimadzu's latest generation interventional lab angiography imaging system, the Trinias, enables advanced imaging cap
Lotus Edge valve
News | Heart Valve Technology| December 07, 2016
December 7, 2016 — Boston Scientific announced a definitive agreement to acquire certain manufacturing assets and cap
Impella CP, Abiomed
News | Hemodynamic Support Devices| December 07, 2016
December 7, 2016 — Abiomed Inc. announced it has expanded its U.S.
Vascular Solutions, Teleflex
Feature | December 07, 2016
December 7, 2016 — Teleflex Inc. and Vascular Solutions Inc.
Siemens Healthineers, PURE Platform, angiography, EVAR, CTO, RSNA 2016
News | Angiography| December 07, 2016
December 7, 2016 — At the 102nd Scientific Assembly and Annual Meeting of the Radiological Society of North America (
Spectranetics, Stellarex 0.014-inch DCB, CE Mark
News | Drug-Eluting Balloons| December 06, 2016
December 6, 2016 — The Spectranetics Corp.
TCT 2016, TCT.16, main arena, late breaking trials, transcatheter cardiovascular therapeutics

There were several hot topics that came out of the 2016 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting Oct. 29 - Nov. 2, which made this month's top 20 list, including several videos. Number 4 on the list of content was the result of the EXCEL Trial key TCT late-breaker, which showed stenting is equal in outcomes to surgery for the first time, when using one of the latest generation drug-eluting stents. 

Feature | December 05, 2016
December 5, 2016 — Here is the list of the top 20 most popular pieces of content on the Diagnostic and Interventional
Cardioband, valtech, Edwards Lifesciences, transcatheter mitral repair, transcatheter tricuspid valve repair, transcatheter annuloplasty

An illustration of how the transcatheter Cardioband System can used as a non-surgical form on annuloplasty repair. 

News | Heart Valve Technology| December 02, 2016
December 2, 2016 — Edwards Lifesciences Corp.
Sponsored Content | Videos | Robotic Systems| November 22, 2016
Corindus Vascular Robotics received U.S.
Overlay Init